Testicular cancer gauge often not used

Mar 17, 2008

A standard part of testicular cancer care isn’t used in more than half of all patients who have the condition, researchers at the University of Michigan Comprehensive Cancer Center have found.

Serum-based tumor markers, which are one indicator of the presence of cancer cells, are helpful in several aspects of the care of patients with testis cancer, including diagnosis, prognostication and surveillance for disease recurrence following treatment. Doctors typically rely on a series of three tumor markers with this type of cancer.

In a review of more than 4,700 testicular cancer cases, a combination of two of these tumor markers were used less than half of the time, while all three tumor markers were measured in just 16 percent of the cases.

The authors of the study found that only about 45 percent of cases used the tumor markers AFP (alpha fetoprotein) and HCG (human chorionic gonadotrophin). Those two were used in conjunction with a third tumor marker, LDH or lactate dehydrogenase, 16 percent of the time. The results are reported in Urologic Oncology, Seminars and Original Investigations.

“Tumor markers play a central role in showing physicians how a patient is responding to treatment and whether the disease has recurred,” says lead author Scott M. Gilbert, M.D., clinical lecturer in the U-M Department of Urology. “We were extremely surprised by the low rates of usage.”

He notes that information obtained from the use of tumor markers impacts the treatment and potentially the outcome in patients with testicular cancer. If markers remain elevated after therapy, it indicates the cancer remains, or if they begin to rise during the surveillance period following successful treatment, the cancer has returned. Gilbert says he and his colleagues regularly check all three tumor markers in their patients.

A majority of the sites in the study failed to show improvement during the study interval, and one – Detroit – experienced a decrease in the use of tumor markers by the end of the study.

The authors point out that the low rates of usage don’t necessarily indicate that the tumor markers were being used as infrequently as the numbers would suggest. One explanation could be that the documentation in medical records was poor, and incidents of tumor marker use were not always recorded, says senior author Brent K. Hollenbeck, M.D., M.S., assistant professor in the U-M Department of Urology.

“Even if it isn’t a problem related to the care of the patients, it is a quality problem at the medical centers that are not recording the data properly. Either way, major improvements need to occur,” he says.

But other data in the study suggest that the reporting of tumor marker use may not be the problem. Using the data from the Surveillance, Epidemiology, and End Results (SEER) program, the researchers found substantially more documentation of PSA use in prostate cancer patients compared to the testicular cancer tumor markers. That information supports the notion that recording may not be the problem, but that the use of testicular cancer markers is in fact very low.

Source: University of Michigan

Explore further: US OKs first-ever DNA alternative to Pap smear (Update)

add to favorites email to friend print save as pdf

Related Stories

Detecting tumor markers easily

Mar 19, 2014

Blood is just teeming with proteins. It's not easy there to identify specialized tumor markers indicating the presence of cancer. A new method now enables diagnostics to be carried out in a single step. Scientists ...

New high-tech glasses detect cancer cells during surgery

Mar 10, 2014

A team of scientists at Washington University School of Medicine in St. Louis (WUSTL) and the University of Arizona (UA) in Tucson led by Samuel Achilefu have created a pair of high-tech glasses that help ...

Researchers develop new sensor for methylated DNA

Mar 14, 2013

Collaborators from Mayo-Illinois Alliance for Technology Based Healthcare have developed a new, single molecule test for detecting methylated DNA. Methylation—the addition of a methyl group of molecules to a DNA strand—is ...

Recommended for you

US OKs first-ever DNA alternative to Pap smear (Update 2)

13 hours ago

U.S. government health regulators have cleared a genetic test from Roche as a first-choice screening option for cervical cancer. It was a role previously reserved for the Pap smear, the decades-old mainstay of women's health.

New breast cancer imaging method promising

19 hours ago

The new PAMmography method for imaging breast cancer developed by the University of Twente's MIRA research institute and the Medisch Spectrum Twente hospital appears to be a promising new method that could ...

Palliation is rarely a topic in studies on advanced cancer

19 hours ago

End-of-life aspects, the corresponding terminology, and the relevance of palliation in advanced cancer are often not considered in publications on randomized controlled trials (RCTs). This is the result of an analysis by ...

User comments : 0

More news stories

Google+ boss leaving the company

The executive credited with bringing the Google+ social network to life is leaving the Internet colossus after playing a key role there for nearly eight years.